...
首页> 外文期刊>Asia-Pacific Biotech News >Axiogenesis In-Licenses Yamanaka Patent Portfolio from iPS Academia Japan
【24h】

Axiogenesis In-Licenses Yamanaka Patent Portfolio from iPS Academia Japan

机译:来自iPS Academia日本的Axiogenesis授权许可Yamanaka专利组合

获取原文
获取原文并翻译 | 示例
           

摘要

German biotech company, Axiogenesis, through an agreement with iPS Academia Japan, has obtained worldwide access to the extensive portfolio of induced pluripotent stem cell (iPSC) technology for iPSC-derived cardiomyocytes and other cell types. The iPSC were pioneered by Professor Shinya Yamanaka, Center for iPS Cell Research and Application (CiRA) at the University of Kyoto, Japan. Axiogenesis specializes in murine embryonic stem cell (ESC) technology and stem cell-derived products. Its proprietaryproduction technology enables the commercialization of pure stem cell-derived cardiomyocytes (branded as Cor.At) and endothelial cells (Endo. At) of outstanding product quality. Currently, Axiogenesis expands and translates its portfolio with iPSC derived human and murine cells.
机译:通过与iPS Academia Japan达成协议,德国生物技术公司Axiogenesis已在全球范围内获得了针对iPSC衍生的心肌细胞和其他细胞类型的诱导性多能干细胞(iPSC)技术的广泛产品组合。 iPSC由日本京都大学iPS细胞研究与应用中心(CiRA)的山中伸弥教授开创。轴突发生专门研究鼠胚胎干细胞(ESC)技术和干细胞衍生产品。其专有的生产技术可以使具有卓越产品质量的纯干细胞来源的心肌细胞(商标为Cor.At)和内皮细胞(Endo.At)商业化。目前,Axiogenesis使用iPSC衍生的人和鼠细胞扩展和翻译其产品组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号